1. Introduction {#sec1}
===============

In Western countries, breast cancer is a major concern and its incidence and mortality rates have been recently influenced by new therapeutic strategies. Our knowledge on cancer precursors, risk biomarkers, and cancer genetics has considerably increased, and prevention strategies are being successfully explored. Unfortunately, over the last decade, breast cancer prevention has been mainly focused on endocrine therapies using selective estrogen receptors modulators (SERMs) and aromatase inhibitors (AIs). Available preventive strategies for nonhormonal breast malignancies, more frequently expressed in BRCA mutation carriers and, in general, in high-risk population, are needed. For these reasons, a great number of novel chemopreventative agents are currently under investigation in order to evaluate their efficacy in this particular cohort of patients.

2. Retinoids {#sec2}
============

In accordance with their recognized role in the regulation of cell growth, differentiation, apoptosis, and their recognized inhibitory effect on cell growth in ER positive and negative breast cancer cells, retinoids (either natural or synthetic compounds structurally related to vitamin A) have long been studied for their chemotherapeutic effect and for their chemopreventive potential in breast cancer setting. Only recently, retinoids have also been applied in this unaffected high-risk population and they have demonstrated to be able to suppress tumor promotion and modify some properties of fully transformed malignant cells by activating and/or repressing specific genes \[[@B1]\]. Retinoids initiate ligand-induced dimerization of retinoid acid receptors (RAR*α*, *β*, and *γ*) and retinoid X receptors (RXR*α*, *β*, and *γ*). Subsequently, receptors bind to retinoid response elements on DNA, and they initiate transactivation of retinoids response target genes \[[@B2]\]. Retinoid receptors are expressed in both normal and malignant breast epithelial cells and are critical for normal development. The mechanism by which retinoids inhibit breast cell growth has not been completely elucidated yet. Given the role played by RAR-*β* in the carcinogenesis of different tumors, its regulation by retinoids has also been advocated as a putative mechanism of action of these agents \[[@B3]\]. However, they have been shown to affect multiple signal transduction pathways, including IGF, TGF*β*, and AP-1-dependent pathways \[[@B4]--[@B8]\], as showed in [Figure 1](#fig1){ref-type="fig"}.

Several preclinical models suggest that retinoids inhibit mammary carcinogenesis in carcinogen-treated rats and in transgenic mice \[[@B9]--[@B11]\]. Recently, in order to reduce retinoids\' side effects, RXR-selective retinoids, commonly known as rexinoids, have been studied as cancer preventive agents. In particular, preclinical studies have demonstrated that these compounds maintain retinoids\' chemopreventive effect, but have greatly reduced toxicity \[[@B12]\]. 9cRA, a retinoid binding both RAR and RXR, has significantly delayed the ER-negative tumor development in SV40 tag mice and MNU-treated rats \[[@B13]\], although it induced significant cutaneous toxicity. In contrast, a RXR-selective retinoid, LGD1069, or bexarotene (Targretin), has suppressed both ER-positive and ER-negative tumor development with minimal toxicity \[[@B14], [@B15]\].

3. Fenretinide (4-HPR) {#sec3}
======================

One of the most promising retinoids to be used in chemoprevention trials is the synthetic amide of retinoic acid fenretinide, *N*-4-hydroxyphenyl retinamide (4-HPR) ([Figure 2](#fig2){ref-type="fig"}).

Fenretinide was first synthesized by Gander in the late 1960s in the United States. Its biologic activity was assayed by Sporn et al., who also showed the preferential accumulation of this drug in the breast, instead of in the liver \[[@B16]\]. The inhibition of chemically induced mammary carcinoma in rats by fenretinide was first described in 1979 \[[@B17]\]. Since then, promising in vitro data and a favorable toxicity profile compared with that of other retinoids have led to the extensive study of fenretinide in chemoprevention trials targeting different organs \[[@B18]\].

Fenretinide has been found to have significant chemopreventive action in a large variety of in vitro and in vivo systems. Both fenretinide and its major metabolite, 4-metoxyphenyl retinamide (MPR), selectively accumulate in the human breast \[[@B19]\]. It should be noticed that some fenretinide-based toxicities could be due also to its hydrolysis so that it returns to retinoic acid in vivo \[[@B20]\]. Nevertheless, it remains a fascinating candidate for breast cancer chemoprevention.

4. Mechanism of Action {#sec4}
======================

High-dose fenretinide is cytotoxic for a variety of different tumor cells in preclinical studies \[[@B21]--[@B23]\], although its accurate mechanism of action is not yet completely understood. However, it has been proposed that it might exert its inhibitory effects by means of both receptor-dependent and -independent mechanism ([Table 1](#tab1){ref-type="table"}, \[[@B24]--[@B26]\]).

Although RAR influence on fenretinide action is highly debated, recent evidence would support the hypothesis according to which a mechanism does not require such relationship. In particular, we would stress the importance of the studies carried out by Giandomenico et al. \[[@B27]\], explaining the role of the stable expression of the dominant negative RAR*α*; by Anding et al. \[[@B28]\], showing that the use of a RAR panantagonist influences an unhydrolyzable analogue of 4-HPR by inducing apoptosis with an independent RAR signaling pathway; by D′Elia et al. \[[@B29]\], assuming resistance to differential responsiveness is present in different cell lines thus indicating that Fenretinide may act through different receptor types. All of these findings seem to diminish the importance of RAR role.

Fenretinide characteristic feature is the ability to inhibit cell growth through the induction of apoptosis rather than differentiation, an effect that is strikingly different from that of the all-*trans* retinoic acid \[[@B30]\]. Moreover, 4-HPR-mediated apoptosis seems to be tissue-specific, so that multiple mechanisms might operate within specific tissues \[[@B25]\]. For example, in ovarian carcinoma cell lines, retinoids may induce apoptosis through the depolarization of the mitochondrial membrane and activation of caspase pathway \[[@B31], [@B32]\], while in the breast and in others cell lines apoptosis seems to be related with a direct molecular interaction with tubulin \[[@B33]\]. Moreover, reactive oxygen species (ROS), such as hydrogen peroxide and superoxide, seem to be critical in mediating apoptosis in different cancer cell types \[[@B34]--[@B36]\]. The ability to increase ROS levels, in particular nitric oxide (NO) by NO synthases (NOS) over the elevation of sphingolipid ceramide levels \[[@B37]\], has been suggested as an explanation of the apoptotic effect of fenretinide. Recently, fenretinide has been shown to be able to induce NO-mediated apoptosis in breast cancer (BRCA-1)-mutated breast cancer cells \[[@B38]\].

Additional mechanisms are under investigations, such as the ability to inhibit cell growth by reducing the expression of growth-stimulating factors or by inducing the expression of growth-inhibitory factors.

A recent proposed surrogate biomarker of fenretinide efficacy is circulating insulin-like growth factor 1 (IGF1). The IGF system plays a pivotal role in cell proliferation of both epithelial and mesenchymal tissues by stimulating mitosis, protecting cells from apoptosis, and maintaining transformed phenotype \[[@B39]\]. Large prospective studies have shown that high circulating levels of IGF1 and lower levels of its major binding protein (IGFBP-3) are associated with a higher risk of developing subsequent premenopausal breast cancer and prostate, lung, and colorectal cancer \[[@B40]--[@B43]\]. This indicates that circulating IGF1 is a key regulator of cell and tumor proliferation for the vast majority of human epithelial cancer. Fenretinide has been shown to inhibit IGF1-stimulated growth of breast cancer cell lines (BCCLs) and to downregulate the IGF system in both ER-positive and ER-negative BCCL \[[@B44]\]. In addition, fenretinide reduces plasma IGF1 in early breast cancer \[[@B45]\]. The expression of HER2 has been recently observed to reduce fenretinide ability to induce apoptosis in breast cancer cells. Moreover, researchers found that HER2 uses active human protein kinase (Akt) to induce cyclooxygenase (COX-2) expression and that inhibition of Akt or COX-2 increased 4-HPR induces apoptosis mediated by NO production \[[@B46]\]. Thus, a combination of 4-HPR with COX-2 inhibitors might be a new strategy to further investigate breast cancer chemoprevention.

5. Pharmacology, Safety, and Tolerability {#sec5}
=========================================

Fenretinide pharmacokinetics and its possible side effects have been tested in several studies. The 5-year administration of the Milan study (see below) provided a vast corpus of information on the long-term safety and tolerability of this retinoid. As a major side effect, it induced a dose-related linear decrease of plasma retinol, associated with diminished retinal adaptation to darkness. In order to minimize this side effect, a 3-day treatment interruption at the end of each month was introduced to increase plasma retinol concentrations, allowing the partial recovery of retinal storage.

However, an accurate and complete evaluation of toxicity was hampered by the lack of a placebo control group. Dermatological, gastrointestinal, visual, and ophthalmologic events were relatively frequent, but were mostly mild. In a recent analysis of the phase III trial \[[@B47]\], the most common adverse events were diminished dark adaptation (cumulative incidence, 19%) and dermatologic disorders (18.6%), such as skin and mucosal dryness, pruritus, and urticaria. Less common events were gastrointestinal symptoms (13%) and alterations of the ocular surface (10.9%). Women in the control group complained of diminished dark adaptation, dermatologic disorders, gastrointestinal symptoms, and alterations of the ocular surface in 2.9%, 2.9%, 5.4%, and 3.2% of the cases, respectively. Interestingly, most side effects decreased with time and were significantly more frequent in postmenopausal women. Importantly, in contrast to other retinoids, prolonged administration of fenretinide is not associated with significant alterations of bone mineral density of the forearm \[[@B48]\]. However, a trend towards an increase in bone resorption markers suggests the need for further assessment at different skeletal sites.

After the completion of a phase I dose-ranging study \[[@B49]\], the 200 mg daily dose was chosen as the safest dose for prevention, as one case of a pathological electroretinogram after a 24-week administration was observed with the 300 mg/day dose \[[@B50]\]. Higher doses, up to 400 mg, have been used in women with metastatic cancer in combination with tamoxifen, with no evident toxicity on liver and lipid profile, but with an increased incidence of nyctalopia \[[@B51], [@B52]\]. Peak levels of 4-HPR occur at approximately 6 h in adults with terminal half-life of approx. 13 h \[[@B50], [@B53]--[@B55]\].

6. Clinical Trials {#sec6}
==================

Since both 4-HPR and 4-MPR are selectively accumulated in the breast, evaluation of fenretinide as a chemopreventive agent in breast cancer has been particularly attractive. The most important clinical trials with fenretinide are mentioned in [Table 2](#tab2){ref-type="table"}. As in the therapeutic setting, where drugs combinations are superior to monochemotherapy, the concept of combining agents with different mechanisms of action in the attempt to increase efficacy while minimizing side effects is a rational approach in chemoprevention. In preclinical models, combined administration of fenretinide and tamoxifen has proven additive and synergistic in both growth inhibition of MCF-7 cells and prevention of MNU-induced mammary carcinomas \[[@B56]\]. Moreover, the activity of 9-*cis*-retinoic acid against MNU-induced mammary tumors in Sprague-Dawley rats is enhanced by the combination with tamoxifen or raloxifene \[[@B11]\]. The safety and the tolerability of the combination of fenretinide and tamoxifen have been investigated in clinical trials in metastatic breast cancer patients \[[@B51]\] and in women at increased risk \[[@B57]\]. The concept of combining agents with different mechanisms of action in the attempt to increase efficacy on complementary molecular targets, while minimizing side effects is increasingly being pursued in breast cancer chemoprevention. A clinical randomized, double-blind, placebo-controlled phase IIb trial with a 2 × 2 factorial design to test this interaction (fenretinide and low-dose tamoxifen) was conducted at the European Institute of Oncology \[[@B58]\]. In spite of the favorable effects on plasma IGF-I levels and mammographic density, this combination did not reduce breast neoplastic events compared to placebo, whereas both single agents, particularly fenretinide, showed numerical reduction in annual odds of breast neoplasms.

Fenretinide (in combination with HRT) was also studied by our group in 226 postmenopausal healthy women, randomized in a two-by-two factorial design to either oral CEE 0.625 mg/day or transdermal E2, 50 microg/day and to fenretinide 100 mg/twice a day or placebo for 12 months \[[@B59]\]. Oral CEE showed more favorable changes than transdermal E2 on circulating breast cancer risk biomarkers, while fenretinide exerted little modulation on most biomarkers.

The most important study where 4-HPR was administrated as a single agent is a multicentric phase III randomized trial, coordinated by the Istituto Nazionale dei Tumori in Milan, started in 1987. Stage I (T1-2 N0) breast cancer patients, aged 33--70 years, who had been operated on for breast cancer within the previous 10 years and had received no systemic adjuvant therapy were eligible \[[@B60]\]. Women were randomly assigned to receive either no treatment or fenretinide given orally at a dose of 200 mg/day for 5 years. A placebo-control arm was not included in the study design because of the large capsule size and the objective nature of the main outcome measure. A 3-day drug stoppage at the end of each month was recommended in order to allow retinol recovery and to minimize dark adaptation impairment. The main outcome measure was the occurrence of contralateral breast cancer as first malignant event. The secondary endpoint was the incidence of ipsilateral breast cancer reappearance, defined as local recurrence in the same quadrant or the occurrence of a second breast malignancy in different quadrants from the primary tumor. Fenretinide showed no effect on contralateral breast cancer occurrence and a nonsignificant 17% reduction in ipsilateral breast tumor reappearance. However, a different effect was noted when the analysis was stratified by menopausal status, with a beneficial trend in premenopausal women on both contralateral and ipsilateral breast cancer (38%) and a reversed trend on contralateral breast cancer in postmenopausal women, as highlighted in [Figure 3](#fig3){ref-type="fig"}. Importantly, the protective effect persisted for up to 15 years (i.e., 10 years after retinoid cessation) \[[@B61]\]. Most notably, the younger the women were, the greater the benefit of fenretinide. Such benefit was associated with a remarkable 50% risk reduction in women aged 40 years or younger, whereas the benefit disappeared after 55 years of age. Interestingly, the incidence of ovarian cancer during the 5-year intervention period was significantly lower in the treatment arm \[[@B62]\]. This effect has been confirmed in an important update \[[@B63]\]. This phase III trial suggested a possible role of fenretinide as a preventive agent acting at different levels of breast carcinogenesis. Admittedly, the results obtained during the phase III trial on our subgroups had not been foreseen when the study was planned. While there are plausible biological explanations for this selective effect, our findings are hypothesis generating and do not have immediate practical clinical implications, although they do provide the rationale for testing the drug\'s efficacy in premenopausal women. Moreover, this protective effect was suggested in women with a high probability of carrying a BRCA-1 mutation. Indeed, fenretinide was highly effective in inhibiting the growth of BRCA-1 mutated breast cancer cell lines \[[@B38]\]. When considering the protective activity of fenretinide on second breast cancer in young women and a similar trend on ovarian cancer, at least during intervention, it appears that women with germline BRCA-1 and BRCA-2 mutations may be ideal candidates for further investigation of this drug.

7. Future Studies {#sec7}
=================

All the collected data as well as fenretinide characteristics make this drug an excellent candidate for chemoprevention of the highlighted subgroup, that is, young healthy women with a high susceptibility to early-onset breast and ovarian cancer, such as BRCA1/2 mutation carriers or women with a significant familial risk. Since the drug activities are probably not strictly influenced by hormonal responsiveness, it may affect also hormone nonresponsive cancers. This may be very useful particularly in case of BRCA 1 mutation carriers.

Several drugs used in prevention settings are usually the same as those used for treatment (adjusting dosage and/or route of administration). This is possible because their mechanism of actions is also active on early-phase carcinogenesis and not only on the inhibition of the tumor growth. This is confirmed by the reduction of second breast cancer found in the reported studies of Veronesi et al. \[[@B60], [@B61]\]. These data make 4-HPR a surrogate marker of primary prevention and a favorable effect of the drug would provide a strong rationale for a primary prevention trial in unaffected women at high risk for breast cancer. Moreover, because its action does not seem to be influenced by the hormonal status, fenretinide might be active in hormone nonresponsive cancer prevention (as occurs in BRCA-1 mutation carriers). Although we obviously need to verify this hypothesis, we think it is an intriguing scenario that could be important in order to identify new pathways related to the efficacy of this drug.

Our Division of Cancer Prevention and Genetics at European Institute of Oncology to Milan has already activated a new phase III prevention trial addressed to this particular cohort of women.

This project is a multicentric randomized phase III placebo-controlled study. A total of 764 healthy women at increased breast cancer risk will be randomized to 4-HPR 200 mg/day versus placebo for 5 years. The subjects will be stratified by participating center and breast cancer risk (BRCA1 mutation versus BRCA2 versus high risk subjects). The accrual estimated time is five years. The design of the study is explained in [Figure 4](#fig4){ref-type="fig"}.

The aim of the proposed trial is to assess the efficacy of fenretinide, in reducing the incidence of breast cancer in healthy young premenopausal women at increased familial/genetic risk for breast cancer; the primary endpoint is to assess the incidence of histologically diagnosed invasive breast cancer and ductal intraepithelial neoplasia.

Secondary endpoints are the incidence of other noninvasive breast disorders (i.e., intraepithelial lobular neoplasia and atypical hyperplasia), ovarian cancer and other cancers.

Moreover, we propose an interdisciplinary research study to further investigate the mechanisms of action of fenretinide in preventing breast cancer. Early intermediate biomarkers of efficacy after 12, 36, and 60 months of treatment, genetic interactions with breast cancer risk modifiers will be explored with the primary goal to identify molecular biomarkers of response prediction. In particular, we will evaluate the percentage change in circulating biomarkers of the IGF system, androgens, retinol binding protein (RBP-4), insulin, blood glucose, and VEGF after 12, 36, and 60 months of treatment. In a subgroup of participants, fine needle aspirate breast biopsy or cells obtained from breast ductal lavage will be drawn at baseline and after a 12-month treatment and the percentage change in RAR expression correlated with apoptosis (caspase-3) and proliferation (Ki-67). Genotyping of single-nucleotide polymorphisms (SNPs) linked to breast cancer risk (MTHFR, COMT, GH, IGFBP-3, AR, and TGF-*β* genes), degree of methylation of RASSAF1 and RAR *β*, and circulating progranulin will be assessed. The results will be correlated with mammographic instrumental measurements, plasma and tissue biomarkers after 1-year treatment. Fenretinide and its metabolites will also be measured to investigate drug bioavailability and compliance. Should the results of this trial confirm that fenretinide is effective in reducing breast and ovarian cancer incidence in this very high risk population, that this effect lasts for many years after treatment, and that the tolerability profile is good, we will have a further preventive chance and a new risk reduction strategy.

Special acknowledgements to Alessandra Rossi and Angela Maniscalco.
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###### 

Mechanism of action of Fenretinide (4-HPR). Corresponding references: \[[@B24]--[@B37]\].

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Mechanism of action                                                                                                          Effect
  ---------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------
  *Receptor dependent*                                                                                                         

   RAR-*α*, *β*, *γ* and RXR-*α*, *β*, *γ* (ligand-activated transcription factors)                                            Regulation of growth, differentiation, and apoptosis

                                                                                                                               

  *Receptor independent*                                                                                                       

   Generation of ROS: hydrogen peroxide and superoxide\                                                                        Apoptosis
   Induction of COX-2 expression by HER2/neu through activation of Akt\                                                        
   Production of nitric oxide by NOS in BRCA 1 mutated breast cancer cells\                                                    
   C-erbB-2 protein and mRNA downregulation\                                                                                   
   Sphingolipid ceramide elevation and membrane synthesis alterations\                                                         
   Mitochondrial damage with cytochrome-C release, disruption of  mitochondrial transmembrane potential, and ROS generation\   
   Caspases activation                                                                                                         

                                                                                                                               

   Induction of growth inhibition factors\                                                                                     Cell growth inhibition
   Inhibition of growth stimulating factors (IGF-1)\                                                                           
   Increased secretion of IGFBPs\                                                                                              
   TGF-*β* secretion                                                                                                           

                                                                                                                               

   Decreased telomerase activity in MNU-induced mammary tumor and  bronchial epithelium of cigarette smokers                   Breast cancer development and progression
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Clinical trials with fenretinide.

  Study                    Design                                  Treatment                                                                             End points                        Outcomes                                                                                                                                                                                References
  ------------------------ --------------------------------------- ------------------------------------------------------------------------------------- --------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------
  Costa et al. (1989)      Phase I, R, PC (60)                     Orally: 100, 200, and 300 mg × 6 months subsequently at 200 mg for another 6 months   Tolerability                      Recommended dose for chemoprevention trials of HPR is 200 mg/die.                                                                                                                       \[[@B49]\]
  Formelli et al. (1989)   Phase II, R, PC (60)                    Orally: 100, 200, and 300 mg × 6 months subsequently at 200 mg for another 6 months   Pharmacokinetic                   HPR treatment lowers retinol and RPB plasma concentrations. This effect is related to HPR levels and is reversible on cessation of HPR administration.                                  \[[@B50]\]
  Veronesi et al. (1999)   Phase III R (2867)                      Orally 200 mg versus no treatment × 5 years                                           Second breast cancer prevention   No statistically significant effect but a possible benefit in premenopausal women.                                                                                                      \[[@B60]\]
  Veronesi et al. (2006)   Phase III, R, 15-year followup (1879)   Orally 200 mg versus no treatment × 5 years; 15-year followup                         Second breast cancer prevention   4-HPR induces a significant risk reduction of second breast cancer in premenopausal women, which is remarkable at younger ages, and persists several years after treatment cessation.   \[[@B61]\]

HPR: Fenretinide; PC: placebo controlled; R: randomized; RBP: retinol-binding protein.
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